Grant A. McArthur

79.7k citations

395 papers · 26.8k indexed · 9 hit papers · h-index 74

Molecular Biology top 0.1%
Oncology top 0.05%
Pulmonary and Respiratory Medicine top 0.2%
Immunology top 0.5%
Cancer Research top 0.2%

Co-authors: Antoni Ribas Keith T. Flaherty Jeffrey A. Sosman Igor Puzanov Paul B. Chapman K. B. Nolop Kevin B. Kim Georgina V. Long
Topics: Melanoma and MAPK Pathways (163 papers)Cutaneous Melanoma Detection and Management (92 papers)Cancer Immunotherapy and Biomarkers (58 papers)
Cited by: Oncology Gastroenterology Molecular Biology
Journals: Nature New England Journal of Medicine Cell
Partner nations: Australia United States United Kingdom

In The Last Decade

Grant A. McArthur

390 papers receiving 26.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 2.6k citations Igor Puzanov, Kevin B. Kim et al. profile →
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

2006 1.9k citations George D. Demetri, Manisha H. Shah et al. profile →
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 1.6k citations Grant A. McArthur, Jeffrey A. Sosman et al. profile →
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

2014 1.5k citations James Larkin, Paolo A. Ascierto et al. profile →
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

2017 1.4k citations Richard A. Scolyer, Georgina V. Long et al. profile →
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

2018 655 citations Georgina V. Long, Richard A. Scolyer et al. profile →
Prognostic Significance of p16 ^INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

2010 571 citations Danny Rischin, Richard J. Young et al. Journal of Clinical Oncology profile →
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

2020 442 citations Caroline Robert, Karl D. Lewis et al. profile →
Melanoma

2015 441 citations Dirk Schadendorf, Grant A. McArthur et al. profile →

Peers

Countries citing papers authored by Grant A. McArthur

Since Specialization

Citations

This map shows the geographic impact of Grant A. McArthur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grant A. McArthur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grant A. McArthur more than expected).

Fields of papers citing papers by Grant A. McArthur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grant A. McArthur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grant A. McArthur. The network helps show where Grant A. McArthur may publish in the future.

Co-authorship network of co-authors of Grant A. McArthur

This figure shows the co-authorship network connecting the top 25 collaborators of Grant A. McArthur. A scholar is included among the top collaborators of Grant A. McArthur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grant A. McArthur. Grant A. McArthur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic 2021 ·Asia-Pacific Journal of Clinical Oncology ·Koen Degeling,Nancy N. Baxter,Jon Emery,Mark A. Jenkins,Fanny Franchini,Peter Gibbs,G. Bruce Mann,Grant A. McArthur,Benjamin Solomon,Maarten J. IJzerman	56
2	Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis 2020 ·The EMBO Journal ·Eric Kusnadi,Anna Trigos,Carleen Cullinane,David L. Goode,Ola Larsson,Jennifer R. Devlin,Keefe T. Chan,David P. De Souza,Malcolm J. McConville,Grant A. McArthur,George Thomas,Elaine Sanij,Gretchen Poortinga,Ross D. Hannan,Katherine M. Hannan,Jian Kang,Richard B. Pearson	28
3	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study 2019 ·Cancer Discovery ·Amit Khot,Natalie Brajanovski,Donald P. Cameron,Nadine Hein,Kylee Maclachlan,Elaine Sanij,John K. C. Lim,John Soong,Emma Link,Piers Blombery,Ella R. Thompson,Andrew Fellowes,Karen E. Sheppard,Grant A. McArthur,Richard B. Pearson,Ross D. Hannan,Gretchen Poortinga,Simon J. Harrison	132
4	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma 2019 ·Clinical Cancer Research ·Antoni Ribas,Adil Daud,Anna C. Pavlick,René González,Karl D. Lewis,Omid Hamid,Thomas F. Gajewski,Igor Puzanov,Matthew Wongchenko,Isabelle Rooney,Jessie J. Hsu,Yibing Yan,(unknown),Grant A. McArthur	30
5	Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib 2017 ·Clinical Cancer Research ·Matthew Wongchenko,Grant A. McArthur,Brigitte Dréno,James Larkin,Paolo A. Ascierto,Jeffrey A. Sosman,Luc Andries,Mark Kockx,Stephen D. Hurst,Ivor Caro,Isabelle Rooney,Priti S. Hegde,Luciana Molinero,Huibin Yue,Ilsung Chang,Lukas C. Amler,Yibing Yan,Antoni Ribas	28
6	Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer 2017 ·Cancer Research ·Zhi L. Teo,(unknown),Sathana Dushyanthen,Franco Caramia,Peter Savas,(unknown),Magnus Zethoven,Balaji Virassamy,Stephen J. Luen,Grant A. McArthur,Wayne A. Phillips,Phillip K. Darcy,Sherene Loi	148
7	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma 2015 ·Cancer Discovery ·Jennifer R. Devlin,Katherine M. Hannan,Nadine Hein,Carleen Cullinane,Eric Kusnadi,Pui Yee Ng,Amee J. George,Jake Shortt,Megan J. Bywater,Gretchen Poortinga,Elaine Sanij,Jian Kang,Denis Drygin,Sean O’Brien,Ricky W. Johnstone,Grant A. McArthur,Ross D. Hannan,Richard B. Pearson	91
8	BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage 2013 ·Clinical Cancer Research ·Victoria Mar,Stephen Q. Wong,Jason Li,Richard A. Scolyer,Catriona McLean,Anthony T. Papenfuss,Richard W. Tothill,Hojabr Kakavand,Graham J. Mann,John F. Thompson,Andreas Behren,Jonathan Cebon,Rory Wolfe,John W. Kelly,Alexander Dobrovic,Grant A. McArthur	100
9	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition 2012 ·Journal of Clinical Oncology ·Lisa Zimmer,Uwe Hillen,Elisabeth Livingstone,Mario E. Lacouture,Klaus J. Busam,Richard D. Carvajal,Friederike Egberts,Axel Hauschild,Mohammed Kashani–Sabet,Simone M. Goldinger,Reinhard Dummer,Georgina V. Long,Grant A. McArthur,André Scherag,Antje Sucker,Dirk Schadendorf	167
10	Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer 2012 ·Clinical Cancer Research ·Quynh‐Thu Le,Richard Fisher,Kelly S. Oliner,Richard J. Young,Hongbin Cao,Christina S. Kong,Edward E. Graves,Rodney J. Hicks,Grant A. McArthur,Lester Peters,Brian O’Sullivan,Amato J. Giaccia,Danny Rischin	41
11	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor 2012 ·Journal of Clinical Oncology ·Kevin B. Kim,Richard Kefford,Anna C. Pavlick,Jeffrey R. Infante,Antoni Ribas,Jeffrey A. Sosman,Leslie A. Fecher,Michael Millward,Grant A. McArthur,Patrick Hwu,René González,Patrick A. Ott,Georgina V. Long,Olivia Gardner,Danièle Ouellet,Yanmei Xu,Douglas J. DeMarini,Ngocdiep T. Le,Kiran Patel,Karl D. Lewis	356
12	Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure 2012 ·Clinical Cancer Research ·George D. Demetri,(unknown),Patrick Schöffski,Manisha H. Shah,Jaap Verweij,Serge Leyvraz,Herbert I. Hurwitz,Antonio López–Pousa,Axel Le Cesne,David S. Goldstein,Luis Paz‐Ares,Jean‐Yves Blay,Grant A. McArthur,Qiang Xu,Xin Huang,Charles S. Harmon,Vanessa Tassell,Darrel P. Cohen,Paolo G. Casali	102
13	Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma 2011 ·Cancer Epidemiology Biomarkers & Prevention ·Richard J. Young,Danny Rischin,Richard Fisher,Grant A. McArthur,Stephen B. Fox,Lester J. Peters,June Corry,Annette M. Lim,Kelly Waldeck,Benjamin Solomon	70
14	RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors 2011 ·Journal of Clinical Oncology ·Patrick A. Oberholzer,Damien Kee,Piotr Dziunycz,Antje Sucker,Nyam Kamsu-Kom,Robert T. Jones,Christine Roden,(unknown),Kristin Ardlie,Emanuele Palescandolo,Adriano Piris,Laura E. MacConaill,Caroline Robert,Günther F.L. Hofbauer,Grant A. McArthur,Dirk Schadendorf,Levi A. Garraway	298
15	In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D ; Pten Deletion Mouse Model of Ovarian Cancer 2011 ·Molecular Cancer Therapeutics ·Kathryn M. Kinross,Daniel V. Brown,Margarete Kleinschmidt,Susan Jackson,James G. Christensen,Carleen Cullinane,Rodney J. Hicks,Ricky W. Johnstone,Grant A. McArthur	62
16	Prognostic Significance of p16 ^INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trialbreakdown → 2010 ·Journal of Clinical Oncology ·Danny Rischin,Richard J. Young,Richard Fisher,Stephen B. Fox,Quynh‐Thu Le,Lester J. Peters,Benjamin Solomon,Jimin Choi,Brian O’Sullivan,Liz Kenny,Grant A. McArthur	571
17	Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model 2010 ·Molecular Cancer Therapeutics ·Carleen Cullinane,Anthony Natoli,(unknown),Nelly Conus,Susan Jackson,J. Brüggen,Paul W. Manley,Grant A. McArthur	27
18	Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial 2009 ·Clinical Cancer Research ·Ian D. Davis,(unknown),Richard Kefford,Michael Millward,Jonathan Cebon,Birte K. Skrumsager,Ulrik Mouritzen,Lasse Tengbjerg Hansen,Kresten Skak,Dorthe Lundsgaard,Klaus Stensgaard Frederiksen,Paul E.G. Kristjansen,Grant A. McArthur	120
19	An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma 2007 ·Clinical Cancer Research ·Ian D. Davis,Birte K. Skrumsager,Jonathan Cebon,Theo Nicholaou,John Barlow,Niels Peter Hundahl Møller,Kresten Skak,Dorthe Lundsgaard,Klaus Stensgaard Frederiksen,Peter Thygesen,Grant A. McArthur	132
20	Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers 2006 ·Cancer Research ·Andrew J. Deans,Kum Kum Khanna,Carolyn J. McNees,Ciro Mercurio,Jörg Heierhorst,Grant A. McArthur	93

About Grant A. McArthur

Grant A. McArthur is a scholar working on Oncology, Molecular Biology and Gastroenterology, having authored 395 papers that have together received 26.8k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (163 papers), Cutaneous Melanoma Detection and Management (92 papers) and Cancer Immunotherapy and Biomarkers (58 papers). The work is most often cited by research in Oncology (15.0k citations), Gastroenterology (1.5k citations) and Molecular Biology (15.2k citations). Grant A. McArthur has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Antoni Ribas, Keith T. Flaherty, Jeffrey A. Sosman, Igor Puzanov, Paul B. Chapman, K. B. Nolop, Kevin B. Kim, Georgina V. Long, Joseph F. Grippo and Richard J. Lee. Their work appears in journals such as Nature, New England Journal of Medicine and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact